Global Markets Direct’s, 'Eye Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Eye Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eye Infections. Eye Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Eye Infections. - A review of the Eye Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eye Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Eye Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Eye Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Eye Infections - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Eye Infections Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Eye Infections 8 Eye Infections Therapeutics under Development by Companies 10 Late Stage Products 12 Comparative Analysis 12 Mid Clinical Stage Products 13 Comparative Analysis 13 Discovery and Pre-Clinical Stage Products 14 Comparative Analysis 14 Eye Infections Therapeutics - Products under Development by Companies 15 Companies Involved in Eye Infections Therapeutics Development 16 Bausch and Lomb Incorporated 16 InSite Vision Incorporated 17 NanoViricides, Inc. 18 Foamix Ltd. 19 Redox Pharmaceutical Corporation 20 Sirnaomics, Inc. 21 SIFI Pharma 22 Dompe Farmaceutici S.p.A. 23 Altacor Ltd. 24 Icon Bioscience, Inc. 25 Eye Infections - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 azithromycin - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 CTC-96 - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 SF-111 - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 SF-101 - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 SF-105 - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 EKCCide-I - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 (tobramycin + prednisolone acetate) - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 tetracycline - Drug Profile 40 Product Description 40 Mechanism of Action 40 RandD Progress 40 STP-601 - Drug Profile 41 Product Description 41 Mechanism of Action 41 RandD Progress 41 AGN-195263 - Drug Profile 42 Product Description 42 Mechanism of Action 42 RandD Progress 42 ALT-005 - Drug Profile 43 Product Description 43 Mechanism of Action 43 RandD Progress 43 dexamethasone acetate + Antibiotic - Drug Profile 44 Product Description 44 Mechanism of Action 44 RandD Progress 44 Eye Infections Therapeutics - Drug Profile Updates 45 Eye Infections Therapeutics - Discontinued Products 46 Eye Infections Therapeutics - Dormant Products 47 Eye Infections - Product Development Milestones 48 Featured News and Press Releases 48 May 10, 2012: Researchers Present Preclinical Data Of Peregrine Pharma's PGN632 At ARVO 2012 48 Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables
Number of Products Under Development for Eye Infections, H1 2013 8 Products under Development for Eye Infections - Comparative Analysis, H1 2013 9 Number of Products under Development by Companies, H1 2013 11 Comparative Analysis by Late Stage Development, H1 2013 12 Comparative Analysis by Mid Clinical Stage Development, H1 2013 13 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 14 Products under Development by Companies, H1 2013 15 Bausch and Lomb Incorporated, H1 2013 16 InSite Vision Incorporated, H1 2013 17 NanoViricides, Inc., H1 2013 18 Foamix Ltd., H1 2013 19 Redox Pharmaceutical Corporation, H1 2013 20 Sirnaomics, Inc., H1 2013 21 SIFI Pharma, H1 2013 22 Altacor Ltd., H1 2013 24 Icon Bioscience, Inc., H1 2013 25 Assessment by Monotherapy Products, H1 2013 26 Assessment by Combination Products, H1 2013 27 Assessment by Stage and Route of Administration, H1 2013 29 Assessment by Stage and Molecule Type, H1 2013 31 Eye Infections Therapeutics - Drug Profile Updates 45 Eye Infections Therapeutics - Discontinued Products 46 Eye Infections Therapeutics - Dormant Products 47
List of Figures
Number of Products under Development for Eye Infections, H1 2013 8 Products under Development for Eye Infections - Comparative Analysis, H1 2013 9 Products under Development by Companies, H1 2013 10 Late Stage Products, H1 2013 12 Mid Clinical Stage Products, H1 2013 13 Discovery and Pre-Clinical Stage Products, H1 2013 14 Assessment by Monotherapy Products, H1 2013 26 Assessment by Combination Products, H1 2013 27 Assessment by Route of Administration, H1 2013 28 Assessment by Stage and Route of Administration, H1 2013 29 Assessment by Molecule Type, H1 2013 30 Assessment by Stage and Molecule Type, H1 2013 31